"Forget venture capital firms investing in promising biotech startups. If we really want to cure cancer, we need pension funds and insurers putting billions of dollars into a fund made up of hundreds of research projects, according to an MIT professor.
"Since 2012, Andrew Lo, a finance professor at MIT’s Sloan School of Management, has been proposing that financiers create a $30 billion “megafund” that invests in early-stage cancer research and development..."
"MOST people agree that a combination of the slowdown in Chinese economic growth and the impending rate hike in the US are to blame for the recent market sell-off, but neither adequately explains its ferocity..."
"Andrew Lo has spent a lot of time peering into Wall Street’s various black boxes and "modeling the endogenous risk among hedge fund strategies." The finance professor at Massachusetts Institute of Technology’s Sloan School of Management and chairman of AlphaSimplex Group LLC shared his thoughts on Friday about the recent spate of volatility in the stock market and what role strategies such as risk parity, trend-following commodity trading advisers and volatility targeting may have played..."
"New research from a pair of MIT economists argues that the Food and Drug Administration, which decides which new drugs get to market through randomized clinical trials, is too one-size-fits-all in its approach to the approval process for treatments for everything from leukemia to the flu. As a result, they say, the agency is too conservative in regulating trials for severe diseases like pancreatic cancer and not conservative enough when it comes to drugs for less dire ones like prostate cancer..."
"As Congress tries to figure out how to speed up the drug approval process, a pair of economists [Andrew Lo and Vahid Montazerhodjat] are asking a different question: Are the criteria we use to choose which drugs are safe and effective too inflexible?
"At the core of this question are two kinds of mistakes that federal regulators can make when deciding whether or not to approve a new drug. The first is pretty straightforward: If they set the evidence bar too low, drugs that don't work and carry dangerous side effects could end up on the market. The second error is less obvious: If they set the bar too high, effective medicines may end up in the dustbin instead of in the hands of patients..."
Culture matters in economic life, and nowhere does it matter as much as in the world of finance. Although many economists acknowledge the importance of culture in shaping the world of finance, and in determining financial outcomes, very few have actually researched this issue carefully. A recent research paper by Andrew Lo of the MIT Sloan School of Management fills this gap.
The interaction between governance, culture and performance is increasingly a topic around asset owner board tables. But little has been written about the relationship between culture and the financial crisis, and how to change culture in financial services organisations. Andrew Lo, professor of finance at MIT, has come up with a proposal to change culture by drawing on traditional risk management protocols used at major financial institutions.
Why do people do bad things at work? A recent paper out from Andrew Lo, a finance professor at MIT's Sloan School of Management, suggests it might be a lot more about the corporate culture than the individuals themselves.
A new report from the Massachusetts Institute of Technology (MIT) is faulting the U.S. government for failing to maintain and grow its investments in basic scientific research, even as European and Asian nations are dramatically increasing their research and development (R&D) spending. Andrew Lo, a finance professor at the MIT Sloan School of Management and one of the report's authors, says the cutbacks in basic research could have a high cost in both national prestige and long-term economic opportunity.